The increasing incidence and changing epidemiology of invasive fungal infections continue
to present many challenges to their effective management. The repertoire of antifungal drugs …

Pneumocystis jirovecii is an atypical fungus exhibiting pulmonary tropism and a highly
defined host specificity. It is generally regarded as an opportunistic microorganism causing …

Background. Pneumocystis jirovecii pneumonia (PJP) is an important infection-related
complication, whose mode of transmission remains uncertain. Methods. We investigated a …

Background The number of patients with non-HIV Pneumocystis pneumonia (PCP) is
increasing with widespread immunosuppressive treatment. We investigated the clinical …

A Pneumocystis jirovecii is one of the most important microorganisms that cause pneumonia
in immunosupressed individuals. The guideline for treatment and prophylaxis of …

Although internal transcribed spacer region (ITS) sequence heterogeneity has been
reported in a few fungal species, it has very rarely been reported in pathogenic fungi and …

Pneumocystis jirovecii pneumonia (PCP) is an important cause of morbidity and mortality in
immunocompromised patients. Sulfa-containing drugs are used for the treatment and …

This study describes the prevalence and genotype distribution of Pneumocystis jirovecii
obtained from nasopharyngeal (NP) swabs from immunocompetent Cuban infants and …

Background. Pneumocystis jirovecii dihydropteroate synthase (DHPS) mutations are
associated with failure of prophylaxis with sulfa drugs. This retrospective study sought to …

Background Pneumocystis pneumonia (PCP) is an opportunistic and potentially life-
threatening infection of immunocompromised individuals. A combination of trimethoprim …